CO2021001277A2 - Inhibidores de triazol glicolato oxidasa - Google Patents
Inhibidores de triazol glicolato oxidasaInfo
- Publication number
- CO2021001277A2 CO2021001277A2 CONC2021/0001277A CO2021001277A CO2021001277A2 CO 2021001277 A2 CO2021001277 A2 CO 2021001277A2 CO 2021001277 A CO2021001277 A CO 2021001277A CO 2021001277 A2 CO2021001277 A2 CO 2021001277A2
- Authority
- CO
- Colombia
- Prior art keywords
- oxidase inhibitors
- glycolate oxidase
- triazole
- useful
- pharmaceutically acceptable
- Prior art date
Links
- 102100038837 2-Hydroxyacid oxidase 1 Human genes 0.000 title abstract 2
- 108010062584 glycollate oxidase Proteins 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 150000003852 triazoles Chemical class 0.000 title 1
- 208000000913 Kidney Calculi Diseases 0.000 abstract 1
- 206010029148 Nephrolithiasis Diseases 0.000 abstract 1
- 208000004777 Primary Hyperoxaluria Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- -1 triazole carboxylic acids Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente invención proporciona ácidos carboxílicos de triazol y compuestos relacionados, y también sales farmacéuticamente aceptables de estos, que son útiles como inhibidores de glicolato oxidasa. También se describen las composiciones farmacéuticas y los métodos para tratar la hiperoxaluria primaria, tipo I (f) y cálculos renales.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862694918P | 2018-07-06 | 2018-07-06 | |
| US201962827573P | 2019-04-01 | 2019-04-01 | |
| PCT/US2019/040690 WO2020010309A1 (en) | 2018-07-06 | 2019-07-05 | Triazole glycolate oxidase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2021001277A2 true CO2021001277A2 (es) | 2021-04-30 |
Family
ID=67441692
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2021/0001277A CO2021001277A2 (es) | 2018-07-06 | 2021-02-05 | Inhibidores de triazol glicolato oxidasa |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11401246B2 (es) |
| EP (1) | EP3817816A1 (es) |
| JP (1) | JP7348705B2 (es) |
| KR (1) | KR20210041564A (es) |
| CN (1) | CN112399873A (es) |
| AU (1) | AU2019297523A1 (es) |
| BR (1) | BR112021000050A2 (es) |
| CA (1) | CA3104529A1 (es) |
| CO (1) | CO2021001277A2 (es) |
| IL (1) | IL279952A (es) |
| MX (1) | MX2021000051A (es) |
| PE (1) | PE20210859A1 (es) |
| SG (1) | SG11202012930RA (es) |
| WO (1) | WO2020010309A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3817816A1 (en) | 2018-07-06 | 2021-05-12 | Orfan Biotech Inc. | Triazole glycolate oxidase inhibitors |
| KR20220097442A (ko) | 2019-11-01 | 2022-07-07 | 기안알엑스 사이언스 인코포레이티드 | 글리콜레이트 산화효소 억제제로서의 헤테로사이클릭 카르복실레이트 화합물 |
| CA3163566A1 (en) * | 2020-01-08 | 2021-07-15 | Elham AKBARIROMANI | Processes for preparing triazole glycolate oxidase inhibitors |
| WO2022066933A1 (en) * | 2020-09-24 | 2022-03-31 | Chinook Therapeutics Canada, Inc. | Pentafluoro-sulfanyl -substituted triazolyl compounds and methods of use thereof |
| TW202339727A (zh) * | 2021-10-11 | 2023-10-16 | 美商坎特羅治療股份有限公司 | 使用１ｈ－１，２，３－***－４－羧酸之治療方法 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0774218B2 (ja) * | 1987-03-02 | 1995-08-09 | 第一製薬株式会社 | ベンゾピラノトリアゾ−ル誘導体 |
| US6187326B1 (en) | 1998-12-29 | 2001-02-13 | Thomas T. Yamashita | Soil amendment composition |
| US7022702B2 (en) | 2000-04-07 | 2006-04-04 | Qlt Inc. | Antiproliferative 1,2,3-thiadiazole compounds |
| SI1682138T1 (sl) | 2003-11-19 | 2011-04-29 | Array Biopharma Inc | HETEROCIKLIÄŚNI INHIBITORJI MEK-a |
| BRPI0515500A (pt) | 2004-09-20 | 2008-07-29 | Xenon Pharmaceuticals Inc | derivados piridazina para inibição de estearoil-coa-desaturase |
| CA2860547A1 (en) | 2012-01-10 | 2013-07-18 | Johannes Cornelius Hermann | Pyridazine amide compounds and their use as syk inhibitors |
| CN103906427B (zh) | 2012-10-25 | 2015-12-02 | 朝日集团控股株式会社 | 胶乳的增产方法 |
| US20140213538A1 (en) | 2013-01-15 | 2014-07-31 | Intermune, Inc. | Lysophosphatidic acid receptor antagonists |
| US9392796B2 (en) | 2013-03-15 | 2016-07-19 | Spogen Biotech Inc. | Plant growth-promoting bacteria and methods of use |
| FR3021843B1 (fr) | 2014-06-06 | 2016-07-08 | Lesaffre & Cie | Methode et composition pour ameliorer la productivite de plantes non legumineuses |
| JP5866035B1 (ja) | 2015-01-08 | 2016-02-17 | アサヒグループホールディングス株式会社 | 有効分げつ促進方法 |
| CN107404883A (zh) | 2015-03-19 | 2017-11-28 | 兴人生命科学株式会社 | 具有植物生长促进或根伸长促进效果且附加值提高效果的酵母抽提物 |
| WO2017100266A1 (en) * | 2015-12-07 | 2017-06-15 | Wake Forest University Health Sciences | Glycolate oxidase inhibitors and methods of use for the treatment of kidney stones |
| IL297802A (en) | 2017-12-29 | 2022-12-01 | Biomarin Pharm Inc | Glycolate oxidase inhibitors to treat the disease |
| AR114065A1 (es) | 2017-12-29 | 2020-07-15 | Orfan Biotech Inc | Inhibidores de glicolato oxidasa y uso de los mismos |
| US11389456B2 (en) | 2018-02-23 | 2022-07-19 | Oxalurx, Inc. | Compounds and methods for treating oxalate-related diseases |
| EP3817816A1 (en) | 2018-07-06 | 2021-05-12 | Orfan Biotech Inc. | Triazole glycolate oxidase inhibitors |
| PE20220901A1 (es) | 2019-06-19 | 2022-05-30 | Biomarin Pharm Inc | Inhibidores de glicolato oxidasa para el tratamiento de enfermedades |
-
2019
- 2019-07-05 EP EP19745452.3A patent/EP3817816A1/en active Pending
- 2019-07-05 PE PE2021000011A patent/PE20210859A1/es unknown
- 2019-07-05 KR KR1020217003486A patent/KR20210041564A/ko unknown
- 2019-07-05 JP JP2021521945A patent/JP7348705B2/ja active Active
- 2019-07-05 MX MX2021000051A patent/MX2021000051A/es unknown
- 2019-07-05 CN CN201980045610.4A patent/CN112399873A/zh active Pending
- 2019-07-05 CA CA3104529A patent/CA3104529A1/en active Pending
- 2019-07-05 BR BR112021000050-0A patent/BR112021000050A2/pt unknown
- 2019-07-05 WO PCT/US2019/040690 patent/WO2020010309A1/en active Application Filing
- 2019-07-05 AU AU2019297523A patent/AU2019297523A1/en active Pending
- 2019-07-05 US US17/255,600 patent/US11401246B2/en active Active
- 2019-07-05 SG SG11202012930RA patent/SG11202012930RA/en unknown
-
2021
- 2021-01-04 IL IL279952A patent/IL279952A/en unknown
- 2021-02-05 CO CONC2021/0001277A patent/CO2021001277A2/es unknown
-
2022
- 2022-06-17 US US17/843,455 patent/US20230143491A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20210403439A1 (en) | 2021-12-30 |
| WO2020010309A9 (en) | 2020-01-30 |
| KR20210041564A (ko) | 2021-04-15 |
| CA3104529A1 (en) | 2020-01-09 |
| SG11202012930RA (en) | 2021-01-28 |
| CN112399873A (zh) | 2021-02-23 |
| JP7348705B2 (ja) | 2023-09-21 |
| WO2020010309A1 (en) | 2020-01-09 |
| IL279952A (en) | 2021-03-01 |
| AU2019297523A1 (en) | 2021-02-25 |
| JP2021530560A (ja) | 2021-11-11 |
| MX2021000051A (es) | 2021-03-25 |
| EP3817816A1 (en) | 2021-05-12 |
| BR112021000050A2 (pt) | 2021-04-06 |
| PE20210859A1 (es) | 2021-05-18 |
| US20230143491A1 (en) | 2023-05-11 |
| US11401246B2 (en) | 2022-08-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2021001277A2 (es) | Inhibidores de triazol glicolato oxidasa | |
| DOP2019000030A (es) | Inhibidores de cdk2/4/6 | |
| CL2017002994A1 (es) | Compuestos de naftiridina como inhibidores de la quinasa jak | |
| UY38196A (es) | Inhibidores de cinasa dependientes de ciclina | |
| UY37656A (es) | Compuestos que inhiben la proteína mcl-1 | |
| CO2019011809A2 (es) | Compuestos de imidazo-piperidina fusionada como inhibidores de jak | |
| NI201600165A (es) | Inhibidores de desmetilasa 1 específica a lisina | |
| EA201890308A1 (ru) | Замещенные азасоединения как ингибиторы irak-4 | |
| EA201890307A1 (ru) | Индазольные и азаиндазольные соединения как ингибиторы irak-4 | |
| CO2017004525A2 (es) | Dihidropirrolopiridinas inhibidoras de ror-gamma | |
| CR20190124A (es) | Inhibidores de ssao de aminopirimidina | |
| EA201790078A1 (ru) | Ингибиторы mnk и связанные с ними способы | |
| CL2020001576A1 (es) | Componentes heterocíclicos bicíclicos sustituidos como inhibidores de prmt5. | |
| EA201792214A1 (ru) | Соединения замещенного хиназолина | |
| MX2018011792A (es) | Compuestos de pirrolotriazina como inhibidores de tyro3, axl y mer (tam). | |
| ECSP18083519A (es) | Inhibidores de bromodominios | |
| EA201790108A1 (ru) | Гетероарильные соединения, пригодные в качестве ингибиторов sumo-активирующего фермента | |
| CO2018011408A2 (es) | Compuestos de pirimidina como inhibidores de la quinasa jak | |
| CL2020000283A1 (es) | Compuestos bicíclicos de pirazol y triazolo como inhibidores de las cinasas jak. | |
| ECSP17026210A (es) | Compuestos de aminopurina sustituida, composiciones del mismo, y métodos de tratamiento con los mismos | |
| MX2020003666A (es) | Compuestos y composiciones para el tratamiento de trastornos hematologicos. | |
| CU20170026A7 (es) | Compuestos derivados de 2-(benzamido/picolinamido/nicotinamido/isonicotinamido)-(2-metil-6-morfolino-(fenil/ (3,4´-bipiridin))-2-il)oxi)etil dihidrógeno fosfato como inhibidores de quinasa raf | |
| UY36713A (es) | Triazoles para el tratamiento de enfermedades desmielinizantes | |
| CL2021001461A1 (es) | Moduladores de trex1 | |
| EA202193015A1 (ru) | Ингибиторы cdk |